Skip to main content

Table 7 Other chemotherapy trials.

From: Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group

Trial N randomized/Evaluable Treatments (dose) and schedule Duration
Weissbach, 1998 [88] NR/175 epirubicin (25 mg/m2) iv q mo NR
   EMP (560 mg) daily  
   mitomycin C (10 mg/m2) iv q mo  
Newling, 1993 [77] 171/161 mitomycin-C (15 mg/m2) iv q 6 wks to progression
   EMP (560 to 700 mg)* po daily  
Murphy, 1988 [75] 180/152 doxorubicin (50 mg/m2) iv q 3 wks cyclophosphamide (500 mg/m2) iv q 3 wks to progression
   cisplatin (50 mg/m2) iv q 3 wks 5-FU (500 mg/m2) iv q 3 wks cyclophosphamide (500 mg/m2) iv q 3 wks  
   methotrexate (100 mg/m2) iv (2 divided doses) q 2 wks  
Loening, 1983 [78] 189/158 methotrexate (100 mg/m2) iv (two divided doses) q wk 12 wks
   cisplatin (60 mg/m2) iv (d1,4,21,24), then once monthly  
   EMP (600 mg/m2) po daily (3 divided doses)  
  1. *Dose of estramustine escalated to 700 mg if 560 mg dose was tolerated for two weeks.
  2. Abbreviations: 5-FU – 5- fluorouracil; d – day; EMP – estramustine phosphate; iv – intravenous; m2 - meters squared; mg – milligrams; mo – month; N – number; NR – not reported; po – per oral; q – every; wk(s) – week (s).
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us